Technology & Devices

Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership announcements that further the company’s commitment to unlocking the power of the genome. Speaking today at the 38th Annual J.P. Morgan Healthcare …

Read More »

Concerto HealthAI and Pfizer Expand Collaboration to Accelerate Real-World Evidence and AI Technologies for Additional Disease Areas

BOSTON, Jan. 10, 2020 /PRNewswire/ — Concerto HealthAI announced an expansion of their existing Precision Oncology collaboration with Pfizer Oncology to advance Concerto HealthAI’s use-case engineered Real-World Data (RWD) for an array of clinical development initiatives across breast, lung, prostate and renal cell carcinoma cancers that will drive innovative new …

Read More »

Xencor and Gilead Enter License Agreement for Use of XmAb Antibody Technologies in Investigational Agents for HIV

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a technology license agreement in which Gilead Sciences, Inc., will access Xencor’s Xtend™ extended half-life and Cytotoxic XmAb® Fc technologies for …

Read More »

Personal Genome Diagnostics and Mayo Clinic Enter Strategic Collaboration to Enhance Patient Care in Oncology

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a strategic collaboration with Mayo Clinic to enhance the development of clinical diagnostic solutions for oncology. Together, PGDx and Mayo Clinic will focus on technology optimization and clinical utility studies for liquid biopsy and tissue-based genomic applications. The two organizations …

Read More »

Schrödinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery

NEW YORK–(BUSINESS WIRE)–Schrödinger and Bayer (BAYN: DE) today announced a five-year technology alliance to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative high-quality drugs. The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the …

Read More »

Personalis Launches a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential therapies and clinical trial options for cancer patients. The Personalis NeXT Dx™ Test is one of the first cancer diagnostic platforms to …

Read More »

CSL Behring to Use SAB Biotherapeutics’ DiversitAb Platform for Novel Drug Discovery

SIOUX FALLS, S.D.–(BUSINESS WIRE)–SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into multiple collaboration and option agreements with global biotherapeutics leader CSL Behring. The collaborations will explore the possibility and the potential of new therapies to treat challenging …

Read More »

Astellas Acquires Xyphos Biosciences, Gaining Access to its ACCEL Technology Platform and Immuno-Oncology Talent

TOKYO and SOUTH SAN FRANCISCO, Calif., Dec. 26, 2019 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Xyphos Biosciences, Inc. (CEO: James Knighton, “Xyphos”) today announced that Astellas has acquired Xyphos. With the acquisition Astellas will gain Xyphos’ novel and proprietary ACCEL (Advanced …

Read More »

Codexis Enters License Agreement with Roche for Enzyme Used in Next Generation Sequencing

REDWOOD CITY, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces a license agreement to provide Roche with Codexis’ EvoT4TM DNA ligase high-performance molecular diagnostic enzyme. This enzyme was developed using Codexis’ proprietary CodeEvolver® protein engineering platform and is expected to be incorporated into …

Read More »

UCB and Accenture Collaborate to Accelerate Data Processing and Help Improve Patient Safety

NEW YORK–(BUSINESS WIRE)–Accenture (NYSE:ACN) and UCB, a global biopharmaceutical company, have collaborated to build a safety solution based on Accenture’s INTIENT™ Pharmacovigilance to accelerate processing of individual patient safety case reports. This will help UCB uncover patient safety impacts from existing treatments and better manage the risks of new drugs and …

Read More »